Anavex Life Sciences Corp. has completed the scale-up manufacturing of Anavex 2-73, its lead compound for the treatment of Alzheimer’s disease. “With sufficient quantities of Anavex 2-73 in hand we are an important step closer to the commencement of Phase I trials, which are scheduled to begin in early 2010,” said Dr. Herve de Kergrohen, chief executive officer of Anavex. “This lead drug candidate shows potential to alter the course of Alzheimer’s disease by usin...